Elite Pharmaceuticals Heads into a Promising Future with Generic Vyanse Approval
Market Growth and FDA Approval Set the Stage for Success
Elite Pharmaceuticals Inc. (ELTP) stands at a pivotal moment as ADHD diagnoses rise globally and the patent for the brand-name drug Vyanse expires in 2023. The company has recently secured FDA approval for its generic version of Vyanse, anticipating a product launch in early 2025.
Image Source: Zacks Investment Research
There is an increasing recognition of ADHD in adults, particularly among women and girls, as medical professionals broaden their understanding of neurodiversity. Medications have proven effective for many patients. Recent media reports have highlighted ongoing challenges in the supply chain for ADHD medications, compounded by new production quotas set by the DEA.
Elite Pharmaceuticals claims to hold over a 10% share of the Adderall market. The company’s goal is to replicate this success with its generic Vyanse. As evidence of its growth, Elite Pharmaceuticals reported revenues of $18.9 million for the period ending September 30, 2024, reflecting a 33.4% increase year-over-year. For the first six months of the year, revenues climbed to $37.7 million, marking a 62.9% rise compared to last year.
The company’s stock currently trades at a trailing 12-month EV/Sales ratio of 6.2, significantly higher than 2.9 for the Zacks sub-industry, 3.8 for the Zacks sector, and 5.4 for the S&P 500 Index. Historically, this stock has fluctuated between 0.7 and 7.4 over the past five years, averaging 2.2 during that time. The primary risk involves the execution and timing of new products entering the market.
Precipio Inc: A Smaller Player with Big Potential
Precipio Inc (PRPO), with a market cap of just $8.8 million, offers a distinctive opportunity. This molecular diagnostics company focuses on blood cancers, aiming to improve the accuracy of diagnostic tests, which grows increasingly important as misdiagnosis becomes an issue in the field.
Image Source: Zacks Investment Research
Precipio’s products, which are less regulated, have the potential for quick scaling and favorable unit economics, often attracting high sales multiples. Currently, PRPO trades at 0.5 times its trailing 12-month sales, far below the Zacks sub-industry average of 1.7, the sector’s 3.9, and the S&P 500’s 5.3. This stock has seen a wide trading range over the past five years, hitting highs of 25.7 and lows of 0.3, with a median of 2.
Recently, Precipio’s total revenue rose 15% year-over-year in Q3 to $5.2 million, driven by a 23% growth in lab services, which represent the majority of its revenue at $4.5 million. This year, the company anticipates reaching break-even status without needing additional capital—a significant achievement in the industry. As part of its growth strategy, Precipio is onboarding three new customers via distribution channels, which should enhance market access. The objective is to sustain revenue growth while improving profitability.
The stock is currently priced at 0.5 times trailing 12-month EV/Sales and 0.8 times P/B, in contrast to the Zacks sub-industry average of 3.7, the sector’s 4.9, and the S&P 500’s 8.6. Moreover, customer concentration represents a risk, as one customer accounted for 14% of the nine-month sales in 2024.
Research Chief Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in the months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Elite Pharmaceuticals Inc. (ELTP): Free Stock Analysis Report
Precipio, Inc. (PRPO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
